PRLD
Prelude Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$275.98M
P/E Ratio
—
EPS
$-1.29
Beta
0.71
52W High
$5.54
52W Low
$0.73
50-Day MA
$3.52
200-Day MA
$2.04
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Prelude Therapeutics Inc
Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized to target key drivers in cancers. The company is headquartered in Wilmington, Delaware.
Fundamentals
| Revenue (TTM) | $12.14M |
| Gross Profit (TTM) | $12.14M |
| EBITDA | $-101.56M |
| Operating Margin | -284.50% |
| Return on Equity | -99.50% |
| Return on Assets | -40.70% |
| Revenue/Share (TTM) | $0.16 |
| Book Value | $0.83 |
| Price-to-Book | 5.34 |
| Price-to-Sales (TTM) | 22.73 |
| EV/Revenue | 16.4 |
| EV/EBITDA | -0.54 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 41.00% |
| Shares Outstanding | $43.77M |
| Float | $29.09M |
| % Insiders | 7.65% |
| % Institutions | 44.48% |
Historical Volatility
HV 10-Day
177.58%
HV 20-Day
149.12%
HV 30-Day
130.05%
HV 60-Day
128.34%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($6.17 target)
1
Strong Buy2
BuyData last updated: 4/29/2026